Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27413227 | 0.89 | AR (0.38) | ARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27411002 | 0.89 | AR (0.40) | ARNPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL27411038 | 0.88 | AR (0.41) | ARNPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL27411004 | 0.87 | AR (0.33) | ARNPC1RAB9ASMN1; SMN2NPSR1 | |
| SCHEMBL26503298 | 0.82 | AR (0.47) | ARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27411008 | 0.81 | AR (0.36) | ARSMN1; SMN2TYR | |
| SCHEMBL27413291 | 0.79 | AR (0.40) | ARNPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL27413224 | 0.78 | AR (0.43) | ARNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26503296 | 0.77 | AR (0.60) | ARNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL27413226 | 0.77 | AR (0.36) | ARNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | AR 1/4885NPC1 3776/4885RAB9A 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.